

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



13th November, 2017

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 13th November 2017.

We refer to the above mentioned subject, we herewith intimate the Exchange that the Board of Directors at their meeting held on 13th November 2017 has considered and approved interalia the following:


- a) Unaudited Financial results and Limited Review Report for the quarter and half year ended 30th September, 2017 which are enclosed herewith.

Kindly note that the meeting commenced at 11:40 AM and concluded at 01:00 PM

This is for the information and records of the Exchange, Please.

Thanking You,
Yours Faithfully,

For **Krebs Biochemicals & Industries Limited**


Harsha Varanasi
Company Secretary

Encl as above

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Ankapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

STAND ALONE FINANCIAL RESULTS FOR THE QUARTER / PERIOD ENDED 30TH SEPTEMBER 2017

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Half Year Ended		For The Year Ending
		30.09.2017 (Un Audited)	30.06.2017 (Un Audited)	30.09.2016 (Un Audited)	30.09.2017 (Un Audited)	30.09.2016 (Un Audited)	31.03.2017 (Audited)
PART - 1							
1	Revenue from Operations						
	a) Net Sales/Income from Operations	261.36	76.38	0.00	337.74	7.14	197.02
	b) Other Operating Income	39.00	39.00	39.00	78.00	78.00	156.00
2	Other Income	-	4.03	1.75	4.03	2.88	7.52
3	Total Income (1+2)	300.36	119.41	40.75	419.77	88.02	360.54
4	Expenses						
	a.Cost of Material Consumed	184.47	30.41	0.69	214.87	0.80	133.99
	b.Changes in inventories of finished goods, work-in-progress	(100.01)	10.10	(6.39)	(89.92)	(2.32)	(41.68)
	c.Employee benefits expense	173.30	150.40	149.36	323.70	273.29	562.59
	d.Finance Costs	124.41	110.19	69.70	234.60	120.37	348.85
	e.Depreciation and Amortisation expense	101.85	101.86	104.09	203.71	208.18	423.37
	f.Other Manufacturing Expenses	199.68	211.35	65.41	411.03	136.70	176.80
	g.Other Expenses	102.68	79.51	80.88	182.19	137.48	321.32
	Total Expenses (4)	786.38	693.81	463.73	1,480.19	874.51	1,925.24
5	Profit / (Loss) before exceptional items and tax (3±4)	(486.03)	(574.39)	(422.99)	(1,060.42)	(786.49)	(1,564.70)
6	Exceptional Itmes:						
	a) Depletion in Value of Inventory	-	(22.52)	(1.88)	(22.52)	(10.25)	(67.56)
	b) Amounts Written Back	-	-	1.41	-	1.41	31.66
	c) Prior Period Income/(Expenditure)	-	3.56	7.46	3.56	7.46	(4.34)
7	Profit / (Loss) from before Tax (5±6)	(486.03)	(593.36)	(415.99)	(1,079.38)	(787.86)	(1,604.94)
8	Tax Expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	Profit / (Loss) for the period (7±8)	(486.03)	(593.36)	(415.99)	(1,079.38)	(787.86)	(1,604.94)
10	Other Comprehensive Income	(22.05)	(21.20)	-	(43.25)	-	451.26
11	Total Comprehensive Income for the period(9±10) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(508.08)	(614.56)	(415.99)	(1,122.63)	(787.86)	(1,153.68)
12	Earning Per Share (before extraordinary Items) (of Rs.10/- each) (not Annualised)						
	(a) Basic	(3.70)	(4.47)	(3.03)	(8.17)	(5.73)	(8.39)
	(b) Diluted	(3.70)	(4.47)	(3.03)	(8.17)	(5.82)	(8.46)
13	Earning Per Share (after extraordinary Items) (of Rs.10/- each) (not Annualised)						
	(a) Basic	(3.70)	(4.47)	(3.03)	(8.17)	(5.73)	(8.39)
	(b) Diluted	(3.70)	(4.47)	(3.03)	(8.17)	(5.82)	(8.46)
	<i>See accompanying notes to the Financial results</i>						



1 The above results have been reviewed by the Audit Committee at its meeting held on 11th November, 2017, and approved by the Board of Directors of the Company at its meeting held on 13th November, 2017. The results are subject to limited review by statutory Auditors.

2 The Company is operating in one segment only hence no segment results have been disclosed.

3 Figures for the quarter ended 30th June 2017 have been regrouped to make them comparable with the current quarter figures. However there is no change in the profit for the quarter ended 30th June 2017.

4 Changes In Work In Process includes Job work Service under process. Job work Service under process increased by Rs. 131.15 lacs for the quarter ended 30th September 2017 in addition to Rs. 43.98 lacs for the quarter ended 30th June 2017 respectively.

5 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.




AVINASH RAVI
 Managing Director
 DIN: 01616152


Place : Mumbai

Date : 13.11.2017

KREBS BIOCHEMICALS & INDUSTRIES LIMITED		
CIN:L24110AP1991PLC103912		
Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031		
Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034		
Statement of Assets and Liabilities		(Rs. In lacs)
Particulars	As at	As at
	30.09.2017 (Un Audited)	31.03.2017 (Audited)
ASSETS		
Non Current Assets		
Property, Plant and Equipment	9,653.63	9,857.34
Capital Work in Progress	543.59	350.31
Other Intangible Assets	338.02	359.88
Financial Assets	95.66	65.44
Other Non Current Assets	263.18	255.88
Total Non Current Assets	10,894.08	10,888.85
Current Assets		
Inventories	669.37	545.49
Financial Assets		
Trade Receivables	140.61	158.83
Cash & Cash Equivalents	24.41	11.71
Others	609.26	602.79
Total Current Assets	1,443.65	1,318.82
Total Assets	12,337.73	12,207.67
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	1,374.43	1,374.43
Other Equity	(2,349.38)	(1,226.74)
Total Equity	(974.95)	147.69
Non Current Liabilities		
Financial Liabilities		
Long Term Borrowings	5,144.45	4,278.74
Provisions	280.40	282.32
Other Non Current Liabilities	4,322.80	4,327.27
Total Non Current Liabilities	9,747.65	8,888.33
Current Liabilities		
Financial Liabilities		
Trade Payables	1,188.97	1,099.30
Other Current Liabilities	2,277.62	1,985.53
Provisions	98.44	86.79
Total Current Liabilities	3,565.03	3,171.62
Total Equity and Liabilities	12,337.73	12,207.67

Place : Mumbai
Date : 13.11.2017

Avinash Ravi

AVINASH RAVI
 Managing Director
 DIN: 01616152



PAVULURI & Co.

CHARTERED ACCOUNTANTS

105, 1st Block, 1st Floor, Divya Shakti Complex,

Ameerpet, Hyderabad - 500 016.

Ph : 040 - 2373 1837, 4025 8691

Fax : 040 - 2374 8729

Email : pavuluriandco@gmail.com

pavuluriandco@hotmail.com

Limited Review Report

**Review Report to
The Board of Directors,
KREBS BIO-CHEMICALS & INDUSTRIES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **M/s. KREBS BIO-CHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30th September, 2017** pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results for the Quarter ended **30th September, 2017** prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No CIR/CFD/CMD/15/2015 dated 30th November 2015 and CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co.


Chartered Accountants

Firm Regn. No: 0121948

(CA. N. RAJESH)

PARTNER

M.No: 223169



Place: Hyderabad

Date: 13.11.2017